Liminatus Pharma, Inc. Class A Common Stock (LIMN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 14.49M |
| Enterprise Value | 15.59M |
| P/E Ratio | -0.23 |
| PEG Ratio | -0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 16.62 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -0.43 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -3.68 |
| Return On Equity | 4.44 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -9.99M |
| Net Income | -10.21M |
| Diluted EPS | -21.5 |
| Total Cash | 3.02M |
| Total Cash/Share | 3.12 |
| Total Debt | 1.44M |
| Total Debt/Equity | 4.8 |
| Current Ratio | 1.12 |
| Book Value Per Share | 0.31 |
| 52-Week Change | -96.96 |
| 52-Week High | 180 |
| 52-Week Low | 4.75 |
| Moving Average 50 Days | 5.84 |
| Moving Average 200 Days | 21.2 |
| Average Volume | 706,551 |
| Shares Outstanding | 1.34M |
| % Held by Institutions | 6.21 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
| Last Split Date | August 21, 2026 |